Interleukin-8 and RANTES inhibit basophil histamine release induced with monocyte chemotactic and activating factor/monocyte chemoattractant peptide-1 and histamine releasing factor.
The objective of this study was to investigate the effect of interleukin-8 (IL-8) and RANTES on basophil histamine release induced with monocyte chemoattractant peptide-1 (MCP-1) and crude histamine releasing factor (HRF). IL-8 induced low levels of histamine release (8.5 +/- 0.5%) from basophils obtained from only six of 20 donors at high concentrations (10(-6) M). RANTES induced histamine release (16 +/- 2%) from basophils of four of 15 donors at 10(-7) M concentration. However, both IL-8 and RANTES inhibited MCP-1 and HRF-induced histamine release from basophils dose-dependently at concentrations of 10(-9) to 10(-7) M. Basophils from all donors showed a significant inhibitory response (greater than 15%). The maximal inhibition of MCP-1 and HRF by IL-8 was 28 +/- 4% and 48 +/- 8%, respectively. The maximal inhibition of MCP-1 and HRF by RANTES was 26 +/- 4% and 43 +/- 6%, respectively. Peripheral blood mononuclear cell-derived HRF was purified into three distinct peaks by reverse-phase high performance liquid chromatography. Peak I contained MCP-1 as judged by binding to an immunoaffinity column that was prepared with anti-MCP-1 antibody. IL-8 inhibited histamine release induced with all three peaks of HRF. The inhibition of histamine release by IL-8 was significantly higher in normal subjects than in allergic patients (59 +/- 9% versus 31 +/- 7%, P less than 0.05). Both IL-8 and RANTES inhibited cytokine-induced histamine release only and did not affect histamine release by anti-IgE, FMLP, and C5a.(ABSTRACT TRUNCATED AT 250 WORDS)
Alam
R
R
Department of Medicine, University of Texas Medical Branch, Galveston 77550.
Forsythe
P A
PA
Lett-Brown
M A
MA
Grant
J A
JA
D000890:Anti-Infective Agents / Q000494:pharmacology; D001491:Basophils / Q000187:drug effects / Q000502:physiology*; D014408:Biomarkers, Tumor; D002469:Cell Separation; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D002630:Chemotactic Factors / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D006967:Hypersensitivity; D066298:In Vitro Techniques; D016209:Interleukin-8 / Q000494:pharmacology*; D007962:Leukocytes / Q000166:cytology / Q000473:pathology / Q000502:physiology; D008222:Lymphokines / Q000494:pharmacology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values; D000090324:Tumor Protein, Translationally-Controlled 1
D000890:Anti-Infective Agents; D014408:Biomarkers, Tumor; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D002630:Chemotactic Factors; D016209:Interleukin-8; D008222:Lymphokines; D011994:Recombinant Proteins; D000090324:Tumor Protein, Translationally-Controlled 1; D009240:N-Formylmethionine Leucyl-Phenylalanine